SlideShare a Scribd company logo
1 of 13
Download to read offline
Regulatory Affairs Excellence:
Staffing & Performance in Medical Device Companies




       Best Practices, LLC Strategic Benchmarking Research




                                                             BEST PRACTICES,   ®
                                                                                   LLC
TABLE OF CONTENTS
I.    Executive Summary
           Research Objective & Methodology
           Key Findings
           Participating Companies Demographics
II.   Respondent Background
           Respondent Demographics
           Regulatory Affairs Reporting Relationship
III. Regulatory Affairs Structure
           Functional Structure
           Corporate Regulatory Affairs FTEs
           Span of Control
IV. Regulatory Function Activities
           Active Regulatory Submissions
           2010 Filings
           Filing Trends
V. Regulatory Function Roles & Responsibilities
           Leading & Supporting Roles
           Corporate Regulatory Affairs Roles
           Storage, Publishing & Translation Solutions
VI. Regulatory Function Investment and Staffing
           2010 Spend & Staffing
           Future Resource Trends
VII. Regulatory Function Outsourcing and Offshoring Trends
           Regulatory Affairs Growth through Resource Efficiencies
VIII. Impact of 510(k) Reform
           Impact of Reform on Resources

                                                                      BEST PRACTICES,   ®
                                                                                            LLC
Research Background and Methodology
Best Practices, LLC conducted this benchmarking study to establish meaningful
benchmarks for the resource levels and the activities scope of the Regulatory Affairs
function for medical device companies.

  Background:
  With the monumental task of ensuring that companies comply with the plethora of global regulations
  and laws pertaining to developing and marketing medical device products, Regulatory Affairs groups
  must rely on their own internal effectiveness and efficiencies to remain productive. Optimal resourcing
  and staffing, including a balance of outsourcing and off-shoring, will help Regulatory Affairs in the
  Medical Technology industry prioritize roles and responsibilities that will be most beneficial to growth.

 Field Research & Insight Development:                                                  Objective:
  Surveyed eight leaders at eight medical device                             To uncover resource and activity




                                                                INFORM
   companies.                                                                 benchmarks as well as forward-
  Conducted three deep-dive executive interviews to                             looking insights about the
   collect qualitative insights from selected survey                           Regulatory Affairs function at
   participants.                                                                 medical device companies.


 Deep Dive Interview Questions:
  1.   What process improvement initiatives are you working on in the Regulatory Affairs function?
  2.   In what areas do lean processes already exist?
  3.   Which structure best supports Regulatory Affairs activities?
  4.   How do you approach outsourcing and off-shoring of Regulatory Affairs activities?
  5.   How do you expect Regulatory Affairs resources to change in response to reform?

                                                                                               BEST PRACTICES,
                                                          3                                                      ®
                                           Copyright © Best Practices, LLC                                          LLC
Universe of Learning: Eight Companies Engaged
Research participants included eight executives from eight medical device companies.
Three executives participated in deep-dive interviews. The key findings and insights are
based on qualitative and quantitative data from their knowledge and experiences.




       Participating Companies: Bausch & Lomb; Becton Dickinson; Boston Scientific;
            Edwards Lifesciences; Ethicon; Medtronic; Roche Diagnostics; Zimmer

                                                                        BEST PRACTICES,
                                                  4                                        ®
                                   Copyright © Best Practices, LLC                            LLC
Key Findings & Insights – 1/3
The following key findings and insights emerged from the data.




 Medical Device Revenue: The average medical device revenue is $7B for the benchmark
Medical Device Revenue: The average medical device revenue is $7B for the benchmark
 class. Half of the medical device revenue comes from U.S. sales.
class. Half of the medical device revenue comes from U.S. sales.
 Regulatory Affairs Reporting Relationship: For 38% of companies, the Regulatory Affairs
Regulatory Affairs Reporting Relationship: For 38% of companies, the Regulatory Affairs
 function reports to C-level management, or the highest level of senior management. For more
function reports to C-level management, or the highest level of senior management. For more
than one-third of companies, the Regulatory Affairs function reports into aacombined Quality
 than one-third of companies, the Regulatory Affairs function reports into combined Quality
 and Regulatory Affairs executive.
and Regulatory Affairs executive.
 Functional Structure: Most Regulatory Affairs functions are business unit centric with RA
Functional Structure: Most Regulatory Affairs functions are business unit centric with RA
employees reporting directly to the business unit they support. A hybrid approach - -one that
 employees reporting directly to the business unit they support. A hybrid approach one that
centralizes planning, information, and coordination, but not staff - -may help increase
 centralizes planning, information, and coordination, but not staff may help increase
 efficiency.
efficiency.
 Corporate Regulatory Affairs Groups: Corporate Regulatory Affairs groups average seven
Corporate Regulatory Affairs Groups: Corporate Regulatory Affairs groups average seven
 FTEs. The groups primarily promote standards, monitor the worldwide regulatory environment,
FTEs. The groups primarily promote standards, monitor the worldwide regulatory environment,
 coordinate internal and external policy advocacy efforts, and advise business unit Regulatory
coordinate internal and external policy advocacy efforts, and advise business unit Regulatory
 Affairs staff.
Affairs staff.


                                                                             BEST PRACTICES,
                                                    5                                           ®
                                     Copyright © Best Practices, LLC                               LLC
Medical Device Revenue Ranges from $1B to $16B
Medical device and technology companies of all sizes face regulatory changes and must
adapt resources to meet demand. Medical device revenue in the benchmark class averages
approximately $7B.

   Q2. Please estimate your company's 2010 annual revenue from medical device sales and related
 services. (Provide all cost figures in U.S. dollars. Use data from most recently completed fiscal year.)



                                                     Estimated Medical Device
                                                         Revenue ($USD):

                            Max                           $16,000,000,000
                            75th Percentile                $9,100,000,000
                            Mean                           $6,995,875,000
                            Median                         $5,950,000,000
                            25th Percentile                $3,565,000,000
                            Min                            $1,447,000,000



(n = 8)

                                                                                     BEST PRACTICES,
                                                        6                                               ®
                                         Copyright © Best Practices, LLC                                   LLC
Most RA Groups Support Corporate Headquarters
Given the importance of Regulatory Affairs to the overall success of a medical device
company, most Regulatory Affairs executives in the benchmark class support efforts at
corporate headquarters. Only 25% primarily support a specific business or operating unit,
which can be attributed to the existing corporate structures at those companies.
                   Q9. Which entity do you primarily support? (Choose one.)


                    A specific
                    business/
                  operating unit,
                       25%




                                                                       The corporate
                                                                       headquarters,
(n = 8)                                                                     75%

                                                                                       BEST PRACTICES,
                                                   7                                                     ®
                                    Copyright © Best Practices, LLC                                         LLC
Most Regulatory Affairs Structures Are BU-Centric
Nearly two-thirds of companies employ a business-unit-centric Regulatory Affairs
structure where RA employees report directly to the business unit or manufacturing site
they support, but also have informal reporting relationships ("dashed line reporting") to a
separate Regulatory hierarchy that ultimately reports to a senior Regulatory Affairs leader.
            Q12. How is Regulatory Affairs structured in your company? (Choose one.)


                                                                           Distributed
                               Other, 13%                                  Regulatory-
                                                                              centric
                                                                         Function: RA is
                                                                           a separate
                                                                             function
             Business-unit-                                              closely aligned
                  Centric                                                     with or
                Regulatory                                               distributed into
             Function: RA                                                  BUs and/or
                employees                                                   sites, 25%
             report directly
               to the BU or
             manufacturing
                 site they
              support, 63%                                               Other:
                                                                         •In transition from business centric
(n = 8)                                                                  to distributed RA centric

                                                                                     BEST PRACTICES,
                                                     8                                                          ®
                                      Copyright © Best Practices, LLC                                              LLC
Most File Regulatory Submissions in >50 Countries
In addition to U.S., EU, Japan and Canada, benchmarked companies file regulatory
submissions in 56 other countries on average. A seamless global IT solution for document
storage is critical to avoid reinventing the wheel for every submission.

Q18. Outside the US, EU, Japan and Canada, in how many additional countries does your company file
                            regulatory submissions for medical devices?



                                                   Number of Additional
                                                   Countries where Filing
                                                  Regulatory Submissions:
                          Max                                    100
                          75th Percentile                         60
                          Mean                                    56
                          Median                                  56
                          25th Percentile                         45
                          Min                                     24



(n = 7)

                                                                               BEST PRACTICES,
                                                     9                                           ®
                                      Copyright © Best Practices, LLC                               LLC
As with EU, Canadian Submissions are Less Taxing on RA
Resources
Canadian licensing costs are much lower per submission than for the U.S. or Japan,
although cost per submission is slightly higher than for the EU.

   Q17. Approximately how much is your Regulatory spend and how many Regulatory FTEs and
        Consultants do you have per each of the following active regulatory submissions?

                          Global RA Spend/                         Global RA FTEs/             Global RA Consultants/
                          Active Submission                       Active Submission              Active Submission
                                                                  Canadian        Canadian       Canadian      Canadian
                        Canadian            Canadian
                                                                  licenses -      licenses -     licenses -    licenses -
                   licenses - Class III licenses - Class II
                                                                  Class III &       Class II     Class III &     Class II
                      & IV devices:          devices:
                                                                 IV devices:       devices:     IV devices:     devices:
 Max                 $1,800,000            $340,000                 17.50           2.70           2.00          0.50
 75th Percentile      $249,251             $229,091                  1.67           1.73           0.21          0.15
 Mean                 $411,342             $162,966                  3.58           1.20           0.37          0.12
 Median               $213,333             $163,102                  1.49           0.93           0.06          0.02
 25th Percentile      $170,383              $84,457                  1.10           0.57           0.04          0.02
 Min                   $26,793              $10,563                  0.55           0.18           0.00          0.00
 (n =                      7                      7                    7               7             7             7)



                                                                                                    BEST PRACTICES,
                                                             10                                                             ®
                                               Copyright © Best Practices, LLC                                                 LLC
PMAs and IDEs Received Consultant Focus
PMAs (see previous slide) and IDEs had the highest Regulatory Consultant FTE levels.
Submission Consultant FTE levels are total RA Consultant FTEs divided by total number of
submissions for each category.
Approximately how many Consultant FTEs were involved in each of the following submissions in 2010?



                                                     Canadian
                                                                     Canadian       Investiga-
                        Japan        Japan Shonin licenses -         licenses -   tional Device    Design     Technical
                     Todokede           (approval    Class III &
                                      applications):
                                                                       Class II    Exemptions     dossiers:     files:
                    (notifications):                  Class IV
                                                                      devices:        (IDEs):
                                                      devices:

  Max                  2.00            5.00            0.40            4.00          4.00          2.00        2.00
  75th Percentile      0.82            0.42            0.19            0.16          1.54          1.50        0.53
  Mean                 0.57            1.01            0.15            0.73          1.13          0.86        0.51
  Median               0.15            0.23            0.12            0.10          0.40          0.40        0.27
  25th Percentile      0.10            0.14            0.02            0.04          0.22          0.30        0.11
  Min                  0.00            0.00            0.00            0.00          0.00          0.00        0.00
    (n =                 6               6               5                6              7            7           7)



                                                                                                    BEST PRACTICES,
                                                             11                                                           ®
                                               Copyright © Best Practices, LLC                                               LLC
RA Leads Submissions, Labeling, FDA Correspondence, and
Registrations
At all organizations, regulatory takes a lead role for filing submissions. Meanwhile, 75
percent of companies have regulatory leading interactions with the FDA on official
correspondence and listings/registrations.

 Q22. For the following responsibilities, does the Regulatory Affairs function lead, support, or play no
                              role? (Choose one role per responsibility.)

                                                                  No Role   Supporting Role    Leading Role
         Regulatory submissions to gain and/or
                                                                                  100%
                 market authorization
                          Labeling/publishing                 25%                        75%
                     FDA Official Correspondent           13% 13%                        75%

                  FDA Listings and Registration           13% 13%                        75%
      Field corrective actions: notification to
                                                          13%               50%                     38%
   regulatory agencies; and follow up reporting
      Responses to Notified Body Observations                               75%                        25%

              Responses to FDA warning letters                                88%                             13%

            Responses to FDA 483 observations                                 88%                             13%
    Audit support (FDA, Notified Bodies, all other
                                                                                  100%
                     agencies)
(n = 8) Complaint handling and MDR reporting                      38%                         63%

                                                                                              BEST PRACTICES,
                                                       12                                                           ®
                                         Copyright © Best Practices, LLC                                               LLC
About Best Practices, LLC

Best Practices, LLC is a research and consulting firm that conducts
work based on the simple yet profound principle that organizations
can chart a course to superior economic performance by studying
the best business practices, operating tactics and winning
                strategies of world-class companies.




                   Best Practices, LLC
      6350 Quadrangle Drive, Suite 200, Chapel Hill, NC 27517
                          919-403-0251
                bestpractices@best-in-class.com
                     www.best-in-class.com




                                                            BEST PRACTICES,   ®
                                                                                  LLC

More Related Content

What's hot

ctd and e ctd submission
ctd and e ctd submissionctd and e ctd submission
ctd and e ctd submissionRohit K.
 
Dossier format and filing.pptx
Dossier format and filing.pptxDossier format and filing.pptx
Dossier format and filing.pptxPrachiSharma575050
 
REGULATORY REQUIREMENTS FOR MARKETING OF COSMETICS BY ROOMA KHALID
REGULATORY REQUIREMENTS FOR MARKETING OF COSMETICS BY ROOMA KHALIDREGULATORY REQUIREMENTS FOR MARKETING OF COSMETICS BY ROOMA KHALID
REGULATORY REQUIREMENTS FOR MARKETING OF COSMETICS BY ROOMA KHALIDRooma Khalid
 
Drug regulatory affairs - 1
Drug regulatory affairs - 1Drug regulatory affairs - 1
Drug regulatory affairs - 1Tanuja Bisht
 
Post approval of drugs
Post approval of drugsPost approval of drugs
Post approval of drugsSunil Boreddy Rx
 
Stability testing protocols
Stability testing protocolsStability testing protocols
Stability testing protocolsMehulJain143
 
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange bookindus university-icri
 
Manufacturing of new drug by loan licence for domestic sale & export
Manufacturing of new drug by loan licence for domestic sale & exportManufacturing of new drug by loan licence for domestic sale & export
Manufacturing of new drug by loan licence for domestic sale & exportPrasad Bhat
 
CTD (common technical document)
CTD (common technical document)CTD (common technical document)
CTD (common technical document)Dr. Jigar Vyas
 
Ich guideline for stability testing
Ich guideline for stability testingIch guideline for stability testing
Ich guideline for stability testingShubham Gore
 
LATEST AMENDMENTS OF THE D&C ACT
LATEST AMENDMENTS OF THE D&C ACTLATEST AMENDMENTS OF THE D&C ACT
LATEST AMENDMENTS OF THE D&C ACTAKHILA PAUL
 
D-U-N-S & FEI Number
D-U-N-S & FEI NumberD-U-N-S & FEI Number
D-U-N-S & FEI NumberShikha Jain
 
Technology Transfer portfolio in Pharmaceutical Industry
Technology Transfer portfolio in Pharmaceutical IndustryTechnology Transfer portfolio in Pharmaceutical Industry
Technology Transfer portfolio in Pharmaceutical IndustryAkshay Jirage
 
Electronic Common Technical Document (eCTD)
Electronic Common Technical Document (eCTD)Electronic Common Technical Document (eCTD)
Electronic Common Technical Document (eCTD)Md. Zakaria Faruki
 
Regulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property RightsRegulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property Rightssantoshnarla
 
Medical device regulations in india
Medical device regulations in indiaMedical device regulations in india
Medical device regulations in indiaSuraj Pamadi
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilGaurav Kr
 

What's hot (20)

ctd and e ctd submission
ctd and e ctd submissionctd and e ctd submission
ctd and e ctd submission
 
Dossier format and filing.pptx
Dossier format and filing.pptxDossier format and filing.pptx
Dossier format and filing.pptx
 
Regulatory aspect of herbal medicines
Regulatory aspect of herbal medicinesRegulatory aspect of herbal medicines
Regulatory aspect of herbal medicines
 
REGULATORY REQUIREMENTS FOR MARKETING OF COSMETICS BY ROOMA KHALID
REGULATORY REQUIREMENTS FOR MARKETING OF COSMETICS BY ROOMA KHALIDREGULATORY REQUIREMENTS FOR MARKETING OF COSMETICS BY ROOMA KHALID
REGULATORY REQUIREMENTS FOR MARKETING OF COSMETICS BY ROOMA KHALID
 
Drug regulatory affairs - 1
Drug regulatory affairs - 1Drug regulatory affairs - 1
Drug regulatory affairs - 1
 
Post approval of drugs
Post approval of drugsPost approval of drugs
Post approval of drugs
 
Stability testing protocols
Stability testing protocolsStability testing protocols
Stability testing protocols
 
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
 
The introduction of an orange book
The introduction of an orange bookThe introduction of an orange book
The introduction of an orange book
 
Manufacturing of new drug by loan licence for domestic sale & export
Manufacturing of new drug by loan licence for domestic sale & exportManufacturing of new drug by loan licence for domestic sale & export
Manufacturing of new drug by loan licence for domestic sale & export
 
CTD (common technical document)
CTD (common technical document)CTD (common technical document)
CTD (common technical document)
 
New Drug Approval in India
New Drug Approval in IndiaNew Drug Approval in India
New Drug Approval in India
 
Ich guideline for stability testing
Ich guideline for stability testingIch guideline for stability testing
Ich guideline for stability testing
 
LATEST AMENDMENTS OF THE D&C ACT
LATEST AMENDMENTS OF THE D&C ACTLATEST AMENDMENTS OF THE D&C ACT
LATEST AMENDMENTS OF THE D&C ACT
 
D-U-N-S & FEI Number
D-U-N-S & FEI NumberD-U-N-S & FEI Number
D-U-N-S & FEI Number
 
Technology Transfer portfolio in Pharmaceutical Industry
Technology Transfer portfolio in Pharmaceutical IndustryTechnology Transfer portfolio in Pharmaceutical Industry
Technology Transfer portfolio in Pharmaceutical Industry
 
Electronic Common Technical Document (eCTD)
Electronic Common Technical Document (eCTD)Electronic Common Technical Document (eCTD)
Electronic Common Technical Document (eCTD)
 
Regulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property RightsRegulatory affairs and Intellectual Property Rights
Regulatory affairs and Intellectual Property Rights
 
Medical device regulations in india
Medical device regulations in indiaMedical device regulations in india
Medical device regulations in india
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazil
 

Viewers also liked

Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDMahesh shinde
 
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...Driving Performance Excellence in the Regulatory Affairs Function at Medical ...
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...Best Practices
 
Regulatory affairs manager perfomance appraisal 2
Regulatory affairs manager perfomance appraisal 2Regulatory affairs manager perfomance appraisal 2
Regulatory affairs manager perfomance appraisal 2tonychoper1404
 
Regulatory Affairs
Regulatory AffairsRegulatory Affairs
Regulatory AffairsShabeenaZaidi
 
Presentation on regulatory affairs 30032013
Presentation on regulatory affairs 30032013Presentation on regulatory affairs 30032013
Presentation on regulatory affairs 30032013Nishodh Saxena Ph. D.
 
Regulatory Affairs.
Regulatory Affairs.Regulatory Affairs.
Regulatory Affairs.Naila Kanwal
 
Regulatory affairs
Regulatory affairsRegulatory affairs
Regulatory affairssekhara
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairsGirish Swami
 
Obtaining Clinical/Regulatory Approval for Medical Devices in a Global Market
Obtaining Clinical/Regulatory Approval for Medical Devices in a Global MarketObtaining Clinical/Regulatory Approval for Medical Devices in a Global Market
Obtaining Clinical/Regulatory Approval for Medical Devices in a Global MarketMedpace
 
Biosimilar Development Regulatory, Analytical, and Clinical Considerations
Biosimilar Development Regulatory, Analytical, and Clinical Considerations Biosimilar Development Regulatory, Analytical, and Clinical Considerations
Biosimilar Development Regulatory, Analytical, and Clinical Considerations SGS
 
Pharma Regulatory Affairs
Pharma Regulatory AffairsPharma Regulatory Affairs
Pharma Regulatory Affairsbiinoida
 
Introduction to Regulatory Affairs - Pauwels Consulting Academy
Introduction to Regulatory Affairs  - Pauwels Consulting AcademyIntroduction to Regulatory Affairs  - Pauwels Consulting Academy
Introduction to Regulatory Affairs - Pauwels Consulting AcademyPauwels Consulting
 
Regulatory Affairs Outsourcing Considerations and Models
Regulatory Affairs Outsourcing Considerations and ModelsRegulatory Affairs Outsourcing Considerations and Models
Regulatory Affairs Outsourcing Considerations and ModelsPaul Kuiken
 
Top 8 regulatory affairs assistant resume samples
Top 8 regulatory affairs assistant resume samplesTop 8 regulatory affairs assistant resume samples
Top 8 regulatory affairs assistant resume samplesfionabeckie8
 

Viewers also liked (20)

Quality and Regulatory Affairs
Quality and Regulatory AffairsQuality and Regulatory Affairs
Quality and Regulatory Affairs
 
Regulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTDRegulatory affairs-Introduction to CTD
Regulatory affairs-Introduction to CTD
 
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...Driving Performance Excellence in the Regulatory Affairs Function at Medical ...
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...
 
Regulatory affairs manager perfomance appraisal 2
Regulatory affairs manager perfomance appraisal 2Regulatory affairs manager perfomance appraisal 2
Regulatory affairs manager perfomance appraisal 2
 
Regulatory Affairs
Regulatory AffairsRegulatory Affairs
Regulatory Affairs
 
Presentation on regulatory affairs 30032013
Presentation on regulatory affairs 30032013Presentation on regulatory affairs 30032013
Presentation on regulatory affairs 30032013
 
Regulatory Affairs.
Regulatory Affairs.Regulatory Affairs.
Regulatory Affairs.
 
Regulatory affairs
Regulatory affairsRegulatory affairs
Regulatory affairs
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairs
 
Regulatory Affairs Profession
Regulatory Affairs ProfessionRegulatory Affairs Profession
Regulatory Affairs Profession
 
Obtaining Clinical/Regulatory Approval for Medical Devices in a Global Market
Obtaining Clinical/Regulatory Approval for Medical Devices in a Global MarketObtaining Clinical/Regulatory Approval for Medical Devices in a Global Market
Obtaining Clinical/Regulatory Approval for Medical Devices in a Global Market
 
Regulatory Affairs as a Career Path
Regulatory Affairs as a Career PathRegulatory Affairs as a Career Path
Regulatory Affairs as a Career Path
 
Biosimilar Development Regulatory, Analytical, and Clinical Considerations
Biosimilar Development Regulatory, Analytical, and Clinical Considerations Biosimilar Development Regulatory, Analytical, and Clinical Considerations
Biosimilar Development Regulatory, Analytical, and Clinical Considerations
 
BioMedical Strategy - Regulatory Presentation
BioMedical Strategy - Regulatory PresentationBioMedical Strategy - Regulatory Presentation
BioMedical Strategy - Regulatory Presentation
 
Pharma Regulatory Affairs
Pharma Regulatory AffairsPharma Regulatory Affairs
Pharma Regulatory Affairs
 
Introduction to Regulatory Affairs - Pauwels Consulting Academy
Introduction to Regulatory Affairs  - Pauwels Consulting AcademyIntroduction to Regulatory Affairs  - Pauwels Consulting Academy
Introduction to Regulatory Affairs - Pauwels Consulting Academy
 
Regulatory Affairs Outsourcing Considerations and Models
Regulatory Affairs Outsourcing Considerations and ModelsRegulatory Affairs Outsourcing Considerations and Models
Regulatory Affairs Outsourcing Considerations and Models
 
Regulatory Affairs powerpoint_slides 031512
Regulatory Affairs powerpoint_slides 031512Regulatory Affairs powerpoint_slides 031512
Regulatory Affairs powerpoint_slides 031512
 
Top 8 regulatory affairs assistant resume samples
Top 8 regulatory affairs assistant resume samplesTop 8 regulatory affairs assistant resume samples
Top 8 regulatory affairs assistant resume samples
 
Pharmaceutical Regulatory Affairs in Australia - by Youssef El-Nazer & Hamid ...
Pharmaceutical Regulatory Affairs in Australia - by Youssef El-Nazer & Hamid ...Pharmaceutical Regulatory Affairs in Australia - by Youssef El-Nazer & Hamid ...
Pharmaceutical Regulatory Affairs in Australia - by Youssef El-Nazer & Hamid ...
 

Similar to Regulatory Affairs Excellence: Staffing and Performance in Medical Device Companies

Quality Staffing & Performance: Ensuring Quality and Safety While Managing Co...
Quality Staffing & Performance: Ensuring Quality and Safety While Managing Co...Quality Staffing & Performance: Ensuring Quality and Safety While Managing Co...
Quality Staffing & Performance: Ensuring Quality and Safety While Managing Co...Best Practices
 
Resource Benchmarks for U.S. Pharmaceutical Managed Care Operations
Resource Benchmarks for U.S. Pharmaceutical Managed Care OperationsResource Benchmarks for U.S. Pharmaceutical Managed Care Operations
Resource Benchmarks for U.S. Pharmaceutical Managed Care OperationsBest Practices, LLC
 
Resource Benchmarks for US Pharma Managed Care Operations Report Summary
Resource Benchmarks for US Pharma Managed Care Operations Report SummaryResource Benchmarks for US Pharma Managed Care Operations Report Summary
Resource Benchmarks for US Pharma Managed Care Operations Report SummaryBest Practices, LLC
 
US Managed Care Staffing & Resourcing Report Summary
US Managed Care Staffing & Resourcing Report SummaryUS Managed Care Staffing & Resourcing Report Summary
US Managed Care Staffing & Resourcing Report SummaryBest Practices
 
Research and Consulting Offerings
Research and Consulting OfferingsResearch and Consulting Offerings
Research and Consulting OfferingsBest Practices
 
Warranty Management Excellence Measuring Performance through Product Return D...
Warranty Management Excellence Measuring Performance through Product Return D...Warranty Management Excellence Measuring Performance through Product Return D...
Warranty Management Excellence Measuring Performance through Product Return D...Best Practices
 
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryMedical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
 
Optimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report SummaryOptimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report SummaryBest Practices
 
Advocacy Excellence: Optimizing Group Structure & Operations Report Summary
Advocacy Excellence: Optimizing Group Structure & Operations Report SummaryAdvocacy Excellence: Optimizing Group Structure & Operations Report Summary
Advocacy Excellence: Optimizing Group Structure & Operations Report SummaryBest Practices
 
Pharma Clinical Affairs Excellence Research Summary
Pharma Clinical Affairs Excellence Research SummaryPharma Clinical Affairs Excellence Research Summary
Pharma Clinical Affairs Excellence Research SummaryBest Practices
 
Human resorce management..
Human resorce management..Human resorce management..
Human resorce management..harshadevarkar
 
Commercial On-Boarding Excellence: Bringing New Employees up to Productivity ...
Commercial On-Boarding Excellence: Bringing New Employees up to Productivity ...Commercial On-Boarding Excellence: Bringing New Employees up to Productivity ...
Commercial On-Boarding Excellence: Bringing New Employees up to Productivity ...Best Practices
 
Mcs report
Mcs reportMcs report
Mcs reportitsme_akku
 
biotech bulletin-2015-spring
biotech bulletin-2015-springbiotech bulletin-2015-spring
biotech bulletin-2015-springBrian Filippini
 
Biotech Bulletin 2Q2015
Biotech Bulletin 2Q2015Biotech Bulletin 2Q2015
Biotech Bulletin 2Q2015Regina M Maxwell
 
Gallup's Notes on Reinventing Performance Management
Gallup's Notes on Reinventing Performance ManagementGallup's Notes on Reinventing Performance Management
Gallup's Notes on Reinventing Performance ManagementLewis Lin 🦊
 
Corporate Affairs Excellence
Corporate Affairs ExcellenceCorporate Affairs Excellence
Corporate Affairs ExcellenceBest Practices, LLC
 
Pharma Public Affairs- Resources Required to Serve the US Market Report Summary
Pharma Public Affairs- Resources Required to Serve the US Market Report SummaryPharma Public Affairs- Resources Required to Serve the US Market Report Summary
Pharma Public Affairs- Resources Required to Serve the US Market Report SummaryBest Practices
 

Similar to Regulatory Affairs Excellence: Staffing and Performance in Medical Device Companies (20)

Quality Staffing & Performance: Ensuring Quality and Safety While Managing Co...
Quality Staffing & Performance: Ensuring Quality and Safety While Managing Co...Quality Staffing & Performance: Ensuring Quality and Safety While Managing Co...
Quality Staffing & Performance: Ensuring Quality and Safety While Managing Co...
 
Resource Benchmarks for U.S. Pharmaceutical Managed Care Operations
Resource Benchmarks for U.S. Pharmaceutical Managed Care OperationsResource Benchmarks for U.S. Pharmaceutical Managed Care Operations
Resource Benchmarks for U.S. Pharmaceutical Managed Care Operations
 
Resource Benchmarks for US Pharma Managed Care Operations Report Summary
Resource Benchmarks for US Pharma Managed Care Operations Report SummaryResource Benchmarks for US Pharma Managed Care Operations Report Summary
Resource Benchmarks for US Pharma Managed Care Operations Report Summary
 
US Managed Care Staffing & Resourcing Report Summary
US Managed Care Staffing & Resourcing Report SummaryUS Managed Care Staffing & Resourcing Report Summary
US Managed Care Staffing & Resourcing Report Summary
 
Research and Consulting Offerings
Research and Consulting OfferingsResearch and Consulting Offerings
Research and Consulting Offerings
 
Warranty Management Excellence Measuring Performance through Product Return D...
Warranty Management Excellence Measuring Performance through Product Return D...Warranty Management Excellence Measuring Performance through Product Return D...
Warranty Management Excellence Measuring Performance through Product Return D...
 
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryMedical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
 
Optimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report SummaryOptimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report Summary
 
Optimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report SummaryOptimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report Summary
 
Advocacy Excellence: Optimizing Group Structure & Operations Report Summary
Advocacy Excellence: Optimizing Group Structure & Operations Report SummaryAdvocacy Excellence: Optimizing Group Structure & Operations Report Summary
Advocacy Excellence: Optimizing Group Structure & Operations Report Summary
 
Pharma Clinical Affairs Excellence Research Summary
Pharma Clinical Affairs Excellence Research SummaryPharma Clinical Affairs Excellence Research Summary
Pharma Clinical Affairs Excellence Research Summary
 
Human resorce management..
Human resorce management..Human resorce management..
Human resorce management..
 
Commercial On-Boarding Excellence: Bringing New Employees up to Productivity ...
Commercial On-Boarding Excellence: Bringing New Employees up to Productivity ...Commercial On-Boarding Excellence: Bringing New Employees up to Productivity ...
Commercial On-Boarding Excellence: Bringing New Employees up to Productivity ...
 
Mcs report
Mcs reportMcs report
Mcs report
 
biotech bulletin-2015-spring
biotech bulletin-2015-springbiotech bulletin-2015-spring
biotech bulletin-2015-spring
 
Biotech Bulletin 2Q2015
Biotech Bulletin 2Q2015Biotech Bulletin 2Q2015
Biotech Bulletin 2Q2015
 
Best Essays Review
Best Essays ReviewBest Essays Review
Best Essays Review
 
Gallup's Notes on Reinventing Performance Management
Gallup's Notes on Reinventing Performance ManagementGallup's Notes on Reinventing Performance Management
Gallup's Notes on Reinventing Performance Management
 
Corporate Affairs Excellence
Corporate Affairs ExcellenceCorporate Affairs Excellence
Corporate Affairs Excellence
 
Pharma Public Affairs- Resources Required to Serve the US Market Report Summary
Pharma Public Affairs- Resources Required to Serve the US Market Report SummaryPharma Public Affairs- Resources Required to Serve the US Market Report Summary
Pharma Public Affairs- Resources Required to Serve the US Market Report Summary
 

More from Best Practices

Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Best Practices
 
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Best Practices
 
Best-in-Class Strategies to Develop Effective Medical Information Groups
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest-in-Class Strategies to Develop Effective Medical Information Groups
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
 
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices
 
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Best Practices
 
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
 
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Best Practices
 
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Best Practices
 
Faster Market Research Approvals
Faster Market Research ApprovalsFaster Market Research Approvals
Faster Market Research ApprovalsBest Practices
 
Benchmarking Professional Medical Education Excellence Structures
Benchmarking Professional Medical Education Excellence StructuresBenchmarking Professional Medical Education Excellence Structures
Benchmarking Professional Medical Education Excellence StructuresBest Practices
 
Models & Trends in REMS Program Success
Models & Trends in REMS Program SuccessModels & Trends in REMS Program Success
Models & Trends in REMS Program SuccessBest Practices
 
Budget Allocation for a Successful Bio-Pharma Product Launch
Budget Allocation for a Successful Bio-Pharma Product LaunchBudget Allocation for a Successful Bio-Pharma Product Launch
Budget Allocation for a Successful Bio-Pharma Product LaunchBest Practices
 
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...Best Practices
 
Library Services Benchmarks - Using Corporate Library Services in Pharma
Library Services Benchmarks - Using Corporate Library Services in PharmaLibrary Services Benchmarks - Using Corporate Library Services in Pharma
Library Services Benchmarks - Using Corporate Library Services in PharmaBest Practices
 
Effective Launch Training Practices for District Sales Managers: Optimize Per...
Effective Launch Training Practices for District Sales Managers: Optimize Per...Effective Launch Training Practices for District Sales Managers: Optimize Per...
Effective Launch Training Practices for District Sales Managers: Optimize Per...Best Practices
 
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...Best Practices in Creating Global Brand for New Products and Ensuring Alignme...
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...Best Practices
 
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...Best Practices
 
Medical Affairs Consortium
Medical Affairs Consortium Medical Affairs Consortium
Medical Affairs Consortium Best Practices
 
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Best Practices
 
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Best Practices
 

More from Best Practices (20)

Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...
 
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...
 
Best-in-Class Strategies to Develop Effective Medical Information Groups
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest-in-Class Strategies to Develop Effective Medical Information Groups
Best-in-Class Strategies to Develop Effective Medical Information Groups
 
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
 
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...
 
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...
 
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...
 
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...
 
Faster Market Research Approvals
Faster Market Research ApprovalsFaster Market Research Approvals
Faster Market Research Approvals
 
Benchmarking Professional Medical Education Excellence Structures
Benchmarking Professional Medical Education Excellence StructuresBenchmarking Professional Medical Education Excellence Structures
Benchmarking Professional Medical Education Excellence Structures
 
Models & Trends in REMS Program Success
Models & Trends in REMS Program SuccessModels & Trends in REMS Program Success
Models & Trends in REMS Program Success
 
Budget Allocation for a Successful Bio-Pharma Product Launch
Budget Allocation for a Successful Bio-Pharma Product LaunchBudget Allocation for a Successful Bio-Pharma Product Launch
Budget Allocation for a Successful Bio-Pharma Product Launch
 
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...
 
Library Services Benchmarks - Using Corporate Library Services in Pharma
Library Services Benchmarks - Using Corporate Library Services in PharmaLibrary Services Benchmarks - Using Corporate Library Services in Pharma
Library Services Benchmarks - Using Corporate Library Services in Pharma
 
Effective Launch Training Practices for District Sales Managers: Optimize Per...
Effective Launch Training Practices for District Sales Managers: Optimize Per...Effective Launch Training Practices for District Sales Managers: Optimize Per...
Effective Launch Training Practices for District Sales Managers: Optimize Per...
 
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...Best Practices in Creating Global Brand for New Products and Ensuring Alignme...
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...
 
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...
 
Medical Affairs Consortium
Medical Affairs Consortium Medical Affairs Consortium
Medical Affairs Consortium
 
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...
 
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...
 

Recently uploaded

Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMintel Group
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxmbikashkanyari
 
Darshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdfDarshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdfShashank Mehta
 
Investment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy CheruiyotInvestment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy Cheruiyotictsugar
 
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024Adnet Communications
 
8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCR8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCRashishs7044
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdfKhaled Al Awadi
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCRashishs7044
 
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort ServiceCall US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Servicecallgirls2057
 
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckPitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckHajeJanKamps
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Anamaria Contreras
 
Chapter 9 PPT 4th edition.pdf internal audit
Chapter 9 PPT 4th edition.pdf internal auditChapter 9 PPT 4th edition.pdf internal audit
Chapter 9 PPT 4th edition.pdf internal auditNhtLNguyn9
 
Fordham -How effective decision-making is within the IT department - Analysis...
Fordham -How effective decision-making is within the IT department - Analysis...Fordham -How effective decision-making is within the IT department - Analysis...
Fordham -How effective decision-making is within the IT department - Analysis...Peter Ward
 
Marketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent ChirchirMarketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent Chirchirictsugar
 
8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCRashishs7044
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCRashishs7044
 

Recently uploaded (20)

Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 Edition
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
 
Darshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdfDarshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdf
 
Investment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy CheruiyotInvestment in The Coconut Industry by Nancy Cheruiyot
Investment in The Coconut Industry by Nancy Cheruiyot
 
Call Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North GoaCall Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North Goa
 
TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024TriStar Gold Corporate Presentation - April 2024
TriStar Gold Corporate Presentation - April 2024
 
8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCR8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCR
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
 
Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)
 
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort ServiceCall US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
 
No-1 Call Girls In Goa 93193 VIP 73153 Escort service In North Goa Panaji, Ca...
No-1 Call Girls In Goa 93193 VIP 73153 Escort service In North Goa Panaji, Ca...No-1 Call Girls In Goa 93193 VIP 73153 Escort service In North Goa Panaji, Ca...
No-1 Call Girls In Goa 93193 VIP 73153 Escort service In North Goa Panaji, Ca...
 
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deckPitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
Pitch Deck Teardown: Geodesic.Life's $500k Pre-seed deck
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.
 
Chapter 9 PPT 4th edition.pdf internal audit
Chapter 9 PPT 4th edition.pdf internal auditChapter 9 PPT 4th edition.pdf internal audit
Chapter 9 PPT 4th edition.pdf internal audit
 
Enjoy ➥8448380779▻ Call Girls In Sector 18 Noida Escorts Delhi NCR
Enjoy ➥8448380779▻ Call Girls In Sector 18 Noida Escorts Delhi NCREnjoy ➥8448380779▻ Call Girls In Sector 18 Noida Escorts Delhi NCR
Enjoy ➥8448380779▻ Call Girls In Sector 18 Noida Escorts Delhi NCR
 
Fordham -How effective decision-making is within the IT department - Analysis...
Fordham -How effective decision-making is within the IT department - Analysis...Fordham -How effective decision-making is within the IT department - Analysis...
Fordham -How effective decision-making is within the IT department - Analysis...
 
Marketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent ChirchirMarketplace and Quality Assurance Presentation - Vincent Chirchir
Marketplace and Quality Assurance Presentation - Vincent Chirchir
 
8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR8447779800, Low rate Call girls in Rohini Delhi NCR
8447779800, Low rate Call girls in Rohini Delhi NCR
 
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
8447779800, Low rate Call girls in New Ashok Nagar Delhi NCR
 

Regulatory Affairs Excellence: Staffing and Performance in Medical Device Companies

  • 1. Regulatory Affairs Excellence: Staffing & Performance in Medical Device Companies Best Practices, LLC Strategic Benchmarking Research BEST PRACTICES, ® LLC
  • 2. TABLE OF CONTENTS I. Executive Summary  Research Objective & Methodology  Key Findings  Participating Companies Demographics II. Respondent Background  Respondent Demographics  Regulatory Affairs Reporting Relationship III. Regulatory Affairs Structure  Functional Structure  Corporate Regulatory Affairs FTEs  Span of Control IV. Regulatory Function Activities  Active Regulatory Submissions  2010 Filings  Filing Trends V. Regulatory Function Roles & Responsibilities  Leading & Supporting Roles  Corporate Regulatory Affairs Roles  Storage, Publishing & Translation Solutions VI. Regulatory Function Investment and Staffing  2010 Spend & Staffing  Future Resource Trends VII. Regulatory Function Outsourcing and Offshoring Trends  Regulatory Affairs Growth through Resource Efficiencies VIII. Impact of 510(k) Reform  Impact of Reform on Resources BEST PRACTICES, ® LLC
  • 3. Research Background and Methodology Best Practices, LLC conducted this benchmarking study to establish meaningful benchmarks for the resource levels and the activities scope of the Regulatory Affairs function for medical device companies. Background: With the monumental task of ensuring that companies comply with the plethora of global regulations and laws pertaining to developing and marketing medical device products, Regulatory Affairs groups must rely on their own internal effectiveness and efficiencies to remain productive. Optimal resourcing and staffing, including a balance of outsourcing and off-shoring, will help Regulatory Affairs in the Medical Technology industry prioritize roles and responsibilities that will be most beneficial to growth. Field Research & Insight Development: Objective:  Surveyed eight leaders at eight medical device To uncover resource and activity INFORM companies. benchmarks as well as forward-  Conducted three deep-dive executive interviews to looking insights about the collect qualitative insights from selected survey Regulatory Affairs function at participants. medical device companies. Deep Dive Interview Questions: 1. What process improvement initiatives are you working on in the Regulatory Affairs function? 2. In what areas do lean processes already exist? 3. Which structure best supports Regulatory Affairs activities? 4. How do you approach outsourcing and off-shoring of Regulatory Affairs activities? 5. How do you expect Regulatory Affairs resources to change in response to reform? BEST PRACTICES, 3 ® Copyright © Best Practices, LLC LLC
  • 4. Universe of Learning: Eight Companies Engaged Research participants included eight executives from eight medical device companies. Three executives participated in deep-dive interviews. The key findings and insights are based on qualitative and quantitative data from their knowledge and experiences. Participating Companies: Bausch & Lomb; Becton Dickinson; Boston Scientific; Edwards Lifesciences; Ethicon; Medtronic; Roche Diagnostics; Zimmer BEST PRACTICES, 4 ® Copyright © Best Practices, LLC LLC
  • 5. Key Findings & Insights – 1/3 The following key findings and insights emerged from the data. Medical Device Revenue: The average medical device revenue is $7B for the benchmark Medical Device Revenue: The average medical device revenue is $7B for the benchmark class. Half of the medical device revenue comes from U.S. sales. class. Half of the medical device revenue comes from U.S. sales. Regulatory Affairs Reporting Relationship: For 38% of companies, the Regulatory Affairs Regulatory Affairs Reporting Relationship: For 38% of companies, the Regulatory Affairs function reports to C-level management, or the highest level of senior management. For more function reports to C-level management, or the highest level of senior management. For more than one-third of companies, the Regulatory Affairs function reports into aacombined Quality than one-third of companies, the Regulatory Affairs function reports into combined Quality and Regulatory Affairs executive. and Regulatory Affairs executive. Functional Structure: Most Regulatory Affairs functions are business unit centric with RA Functional Structure: Most Regulatory Affairs functions are business unit centric with RA employees reporting directly to the business unit they support. A hybrid approach - -one that employees reporting directly to the business unit they support. A hybrid approach one that centralizes planning, information, and coordination, but not staff - -may help increase centralizes planning, information, and coordination, but not staff may help increase efficiency. efficiency. Corporate Regulatory Affairs Groups: Corporate Regulatory Affairs groups average seven Corporate Regulatory Affairs Groups: Corporate Regulatory Affairs groups average seven FTEs. The groups primarily promote standards, monitor the worldwide regulatory environment, FTEs. The groups primarily promote standards, monitor the worldwide regulatory environment, coordinate internal and external policy advocacy efforts, and advise business unit Regulatory coordinate internal and external policy advocacy efforts, and advise business unit Regulatory Affairs staff. Affairs staff. BEST PRACTICES, 5 ® Copyright © Best Practices, LLC LLC
  • 6. Medical Device Revenue Ranges from $1B to $16B Medical device and technology companies of all sizes face regulatory changes and must adapt resources to meet demand. Medical device revenue in the benchmark class averages approximately $7B. Q2. Please estimate your company's 2010 annual revenue from medical device sales and related services. (Provide all cost figures in U.S. dollars. Use data from most recently completed fiscal year.) Estimated Medical Device Revenue ($USD): Max $16,000,000,000 75th Percentile $9,100,000,000 Mean $6,995,875,000 Median $5,950,000,000 25th Percentile $3,565,000,000 Min $1,447,000,000 (n = 8) BEST PRACTICES, 6 ® Copyright © Best Practices, LLC LLC
  • 7. Most RA Groups Support Corporate Headquarters Given the importance of Regulatory Affairs to the overall success of a medical device company, most Regulatory Affairs executives in the benchmark class support efforts at corporate headquarters. Only 25% primarily support a specific business or operating unit, which can be attributed to the existing corporate structures at those companies. Q9. Which entity do you primarily support? (Choose one.) A specific business/ operating unit, 25% The corporate headquarters, (n = 8) 75% BEST PRACTICES, 7 ® Copyright © Best Practices, LLC LLC
  • 8. Most Regulatory Affairs Structures Are BU-Centric Nearly two-thirds of companies employ a business-unit-centric Regulatory Affairs structure where RA employees report directly to the business unit or manufacturing site they support, but also have informal reporting relationships ("dashed line reporting") to a separate Regulatory hierarchy that ultimately reports to a senior Regulatory Affairs leader. Q12. How is Regulatory Affairs structured in your company? (Choose one.) Distributed Other, 13% Regulatory- centric Function: RA is a separate function Business-unit- closely aligned Centric with or Regulatory distributed into Function: RA BUs and/or employees sites, 25% report directly to the BU or manufacturing site they support, 63% Other: •In transition from business centric (n = 8) to distributed RA centric BEST PRACTICES, 8 ® Copyright © Best Practices, LLC LLC
  • 9. Most File Regulatory Submissions in >50 Countries In addition to U.S., EU, Japan and Canada, benchmarked companies file regulatory submissions in 56 other countries on average. A seamless global IT solution for document storage is critical to avoid reinventing the wheel for every submission. Q18. Outside the US, EU, Japan and Canada, in how many additional countries does your company file regulatory submissions for medical devices? Number of Additional Countries where Filing Regulatory Submissions: Max 100 75th Percentile 60 Mean 56 Median 56 25th Percentile 45 Min 24 (n = 7) BEST PRACTICES, 9 ® Copyright © Best Practices, LLC LLC
  • 10. As with EU, Canadian Submissions are Less Taxing on RA Resources Canadian licensing costs are much lower per submission than for the U.S. or Japan, although cost per submission is slightly higher than for the EU. Q17. Approximately how much is your Regulatory spend and how many Regulatory FTEs and Consultants do you have per each of the following active regulatory submissions? Global RA Spend/ Global RA FTEs/ Global RA Consultants/ Active Submission Active Submission Active Submission Canadian Canadian Canadian Canadian Canadian Canadian licenses - licenses - licenses - licenses - licenses - Class III licenses - Class II Class III & Class II Class III & Class II & IV devices: devices: IV devices: devices: IV devices: devices: Max $1,800,000 $340,000 17.50 2.70 2.00 0.50 75th Percentile $249,251 $229,091 1.67 1.73 0.21 0.15 Mean $411,342 $162,966 3.58 1.20 0.37 0.12 Median $213,333 $163,102 1.49 0.93 0.06 0.02 25th Percentile $170,383 $84,457 1.10 0.57 0.04 0.02 Min $26,793 $10,563 0.55 0.18 0.00 0.00 (n = 7 7 7 7 7 7) BEST PRACTICES, 10 ® Copyright © Best Practices, LLC LLC
  • 11. PMAs and IDEs Received Consultant Focus PMAs (see previous slide) and IDEs had the highest Regulatory Consultant FTE levels. Submission Consultant FTE levels are total RA Consultant FTEs divided by total number of submissions for each category. Approximately how many Consultant FTEs were involved in each of the following submissions in 2010? Canadian Canadian Investiga- Japan Japan Shonin licenses - licenses - tional Device Design Technical Todokede (approval Class III & applications): Class II Exemptions dossiers: files: (notifications): Class IV devices: (IDEs): devices: Max 2.00 5.00 0.40 4.00 4.00 2.00 2.00 75th Percentile 0.82 0.42 0.19 0.16 1.54 1.50 0.53 Mean 0.57 1.01 0.15 0.73 1.13 0.86 0.51 Median 0.15 0.23 0.12 0.10 0.40 0.40 0.27 25th Percentile 0.10 0.14 0.02 0.04 0.22 0.30 0.11 Min 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (n = 6 6 5 6 7 7 7) BEST PRACTICES, 11 ® Copyright © Best Practices, LLC LLC
  • 12. RA Leads Submissions, Labeling, FDA Correspondence, and Registrations At all organizations, regulatory takes a lead role for filing submissions. Meanwhile, 75 percent of companies have regulatory leading interactions with the FDA on official correspondence and listings/registrations. Q22. For the following responsibilities, does the Regulatory Affairs function lead, support, or play no role? (Choose one role per responsibility.) No Role Supporting Role Leading Role Regulatory submissions to gain and/or 100% market authorization Labeling/publishing 25% 75% FDA Official Correspondent 13% 13% 75% FDA Listings and Registration 13% 13% 75% Field corrective actions: notification to 13% 50% 38% regulatory agencies; and follow up reporting Responses to Notified Body Observations 75% 25% Responses to FDA warning letters 88% 13% Responses to FDA 483 observations 88% 13% Audit support (FDA, Notified Bodies, all other 100% agencies) (n = 8) Complaint handling and MDR reporting 38% 63% BEST PRACTICES, 12 ® Copyright © Best Practices, LLC LLC
  • 13. About Best Practices, LLC Best Practices, LLC is a research and consulting firm that conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC 6350 Quadrangle Drive, Suite 200, Chapel Hill, NC 27517 919-403-0251 bestpractices@best-in-class.com www.best-in-class.com BEST PRACTICES, ® LLC